bioactive small molecules Search Results


bioactive compound library  (TargetMol)
95
TargetMol bioactive compound library
Bioactive Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bioactive compound library/product/TargetMol
Average 95 stars, based on 1 article reviews
bioactive compound library - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
targetmol bioactive library  (TargetMol)
94
TargetMol targetmol bioactive library
Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol <t>Bioactive</t> Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2
Targetmol Bioactive Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/targetmol bioactive library/product/TargetMol
Average 94 stars, based on 1 article reviews
targetmol bioactive library - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
bioactive compounds  (TargetMol)
93
TargetMol bioactive compounds
Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol <t>Bioactive</t> Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2
Bioactive Compounds, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bioactive compounds/product/TargetMol
Average 93 stars, based on 1 article reviews
bioactive compounds - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
de novo design of bioactive small molecules by artificial intelligence  (Merck KGaA)
90
Merck KGaA de novo design of bioactive small molecules by artificial intelligence
Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol <t>Bioactive</t> Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2
De Novo Design Of Bioactive Small Molecules By Artificial Intelligence, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/de novo design of bioactive small molecules by artificial intelligence/product/Merck KGaA
Average 90 stars, based on 1 article reviews
de novo design of bioactive small molecules by artificial intelligence - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
small collections of bioactive molecules  (Broad Institute Inc)
90
Broad Institute Inc small collections of bioactive molecules
Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol <t>Bioactive</t> Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2
Small Collections Of Bioactive Molecules, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/small collections of bioactive molecules/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
small collections of bioactive molecules - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
bioactive small molecule scm-198  (Cardiovascular Systems Inc)
90
Cardiovascular Systems Inc bioactive small molecule scm-198
Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol <t>Bioactive</t> Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2
Bioactive Small Molecule Scm 198, supplied by Cardiovascular Systems Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bioactive small molecule scm-198/product/Cardiovascular Systems Inc
Average 90 stars, based on 1 article reviews
bioactive small molecule scm-198 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
small bioactive molecules  (Bioactive Ingredients)
90
Bioactive Ingredients small bioactive molecules
Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol <t>Bioactive</t> Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2
Small Bioactive Molecules, supplied by Bioactive Ingredients, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/small bioactive molecules/product/Bioactive Ingredients
Average 90 stars, based on 1 article reviews
small bioactive molecules - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
bioactive small molecules  (DWK Life Sciences)
90
DWK Life Sciences bioactive small molecules
Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol <t>Bioactive</t> Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2
Bioactive Small Molecules, supplied by DWK Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bioactive small molecules/product/DWK Life Sciences
Average 90 stars, based on 1 article reviews
bioactive small molecules - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
photothermal antimicrobial guar gum hydrogel cross-linked by bioactive small molecule lysine  (Zhiyuan Chemical Co Ltd)
90
Zhiyuan Chemical Co Ltd photothermal antimicrobial guar gum hydrogel cross-linked by bioactive small molecule lysine
Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol <t>Bioactive</t> Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2
Photothermal Antimicrobial Guar Gum Hydrogel Cross Linked By Bioactive Small Molecule Lysine, supplied by Zhiyuan Chemical Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/photothermal antimicrobial guar gum hydrogel cross-linked by bioactive small molecule lysine/product/Zhiyuan Chemical Co Ltd
Average 90 stars, based on 1 article reviews
photothermal antimicrobial guar gum hydrogel cross-linked by bioactive small molecule lysine - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
bioactive small molecules  (AK Scientific)
90
AK Scientific bioactive small molecules
Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol <t>Bioactive</t> Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2
Bioactive Small Molecules, supplied by AK Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bioactive small molecules/product/AK Scientific
Average 90 stars, based on 1 article reviews
bioactive small molecules - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
bioactive small molecules  (Syngenta)
90
Syngenta bioactive small molecules
Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol <t>Bioactive</t> Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2
Bioactive Small Molecules, supplied by Syngenta, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bioactive small molecules/product/Syngenta
Average 90 stars, based on 1 article reviews
bioactive small molecules - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
small molecule inhibitors/agonists  (Bioactive Ingredients)
90
Bioactive Ingredients small molecule inhibitors/agonists
Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol <t>Bioactive</t> Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2
Small Molecule Inhibitors/Agonists, supplied by Bioactive Ingredients, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/small molecule inhibitors/agonists/product/Bioactive Ingredients
Average 90 stars, based on 1 article reviews
small molecule inhibitors/agonists - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol Bioactive Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2

Journal: Alzheimer's Research & Therapy

Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen

doi: 10.1186/s13195-026-01960-6

Figure Lengend Snippet: Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol Bioactive Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2

Article Snippet: We then screened a subset of ~ 900 molecules from the TargetMol Bioactive Library and identified two main groups compounds.

Techniques: Activity Assay, Disruption, Concentration Assay, Control